Clinical Trial Update: Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assesses the immunogenicity of Gardasil-9 in people with idiopathic CD4 T cell lymphocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Cd4 Cell Lymphocytopenia

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Idiopathic CD4 T Cell Lymphocytopenia | Phase 2 | Status: ACTIVE_NOT_RECRUITING